← All trials
NCT06274398
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 16, 2024
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Feb 23, 2024
- Last posted
- Feb 23, 2024
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eastern Virginia Medical SchoolLead sponsor
- Emory UniversityCollaborator
- Emory UniversityOfficial
- Centers for Disease Control and Prevention (CDC)Official
- Centers for Disease Control and Prevention (CDC)Collaborator
- CONRADCollaborator
- CONRADOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.